Iconic Labs PLC Issue of Equity (5345B)
02 Junho 2023 - 9:20AM
UK Regulatory
TIDMICON
RNS Number : 5345B
Iconic Labs PLC
02 June 2023
Iconic Labs PLC
("Iconic" or the "Company")
EHGOSF Subscribes for a GBP180,000 Sixth Tranche Under GBP3
million Financing Facility
and Conversion of Notes
Iconic Labs PLC (LSE: ICON) announces that the European High
Growth Opportunities Securitization Fund ("EHGOSF") has subscribed
for a GBP180,000 sixth tranche of convertible notes under the GBP3
million financing facility (the "Facility") that was entered into
on 28 September 2022. This subscription takes the total subscribed
under the Facility to GBP1,030,000.
In exchange, Iconic will issue 180 convertible notes to EHGOSF
along with 3,000,000,000 warrants with an exercise price of
GBP0.00003.
The funds under this sixth tranche will be used to meet Iconic's
obligations under the CVA, for operational purposes, and
preparation of an FCA approved prospectus which will enable Iconic
to issue further Ordinary Shares pursuant to its obligations to
unsecured creditors under the CVA, EHGSOF under the Facility,
various parties under the settlement deeds, and management for
outstanding fees.
In addition, Iconic announces that it has received a valid
conversion notice from the EHGSOF ("Conversion Notice")..
The Conversion Notice was dated 1 June 2023 and provides for 30
Convertible Notes to be converted into 1,200,000,000 ordinary
shares of GBP0.00001 ("Ordinary Shares") in the Company at a
conversion price of GBP0.000025 at the aggregate principal amount
of GBP30,000.
Application is being made for the 1,200,000,000 new Ordinary
Shares to be admitted to trading on the Main Market of the London
Stock Exchange which is expected to be on or around 8 June 2023.
These shares rank pari passu with the existing Ordinary Shares of
the Company.
Following the issue of these shares, the Company's issued
ordinary share capital shall consist of 46,306,916,660 Ordinary
Shares. The figure of 46,306,916,660 represents the total voting
rights in the Company and should be used by shareholders as the
denominator for the calculation by which they can determine if they
are required to notify their interest in, or a change to their
interest in, the Company under the Financial Conduct Authority's
Disclosure Guidance & Transparency Rules.
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with
the Company's obligations under Article 17 of MAR.
For any further information or enquiries please contact:
ir@iconiclabs.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFTMTTMTBMBLJ
(END) Dow Jones Newswires
June 02, 2023 08:20 ET (12:20 GMT)
Iconic Labs (LSE:ICON)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Iconic Labs (LSE:ICON)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025
